-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NIM-1324 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NIM-1324 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NIM-1324 in Rheumatoid ArthritisDrug Details:NIM-1324 is under development for the treatment of rheumatoid...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NIM-1324 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NIM-1324 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NIM-1324 in Systemic Lupus ErythematosusDrug Details:NIM-1324 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BT-8009 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BT-8009 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BT-8009 in Transitional Cell Carcinoma (Urothelial Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CX-904 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CX-904 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CX-904 in Solid Tumor Drug Details:CX-904 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Measles [strain Edmonstons-Zagreb] + Rubella [strain RA-27]) Vaccine in Rubella (German Measles)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Measles [strain Edmonstons-Zagreb] + Rubella [strain RA-27]) Vaccine in Rubella (German Measles) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Measles [strain Edmonstons-Zagreb]...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-BBN in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAR-BBN in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SAR-BBN in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acebilustat in Lymphedema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acebilustat in Lymphedema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Acebilustat in LymphedemaDrug Details:Acebilustat (formerly CTX-4430, EP-501) is under development for the treatment of bullous...
-
Analyst Opinions
UK Retail Banking Competitor Benchmarking – Financial Performance, Customer Relationships, Customer Satisfaction and Actionable Steps
United Kingdom (UK) Retail Banking Market Report Overview The UK retail banking industry had a good year in 2022 as most banks increased their net interest income and its average net interest margin (NIM) while reducing its cost/income ratio between 2021 and 2022. This report explores both the financial performance of and customer attitudes toward UK retail banks. Key statistics such as total divisional assets and cost/income ratios are provided for all major players, alongside market shares for key products....
-
Product Insights
Telangana Gov – Hyderabad NIMS Hospital Expansion – Telangana
Equip yourself with the essential tools needed to make informed and profitable decisions with our Telangana Gov - Hyderabad NIMS Hospital Expansion - Telangana report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Sector Analysis
United Kingdom (UK) Mortgage Market 2020 – Review, Forecasts, and Future Opportunities
The UK mortgage market was characterized by an initial slowdown in mortgage activity in 2020, followed by a significant rise, with overall mortgage balances outstanding 3.1% higher in January 2021 than at the same point in 2020. This can largely be attributed to changes in stamp duty, creating an incentive for consumers to buy property. Residential mortgage lending growth is set to continue at a steady pace, reaching £1,730bn in 2025 - up from £1,499bn in 2020 at a compound...